VANCOUVER, July 13 /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that it has signed a collaborative agreement with the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic correlations in severe sepsis patients. The agreement focuses on the continued development of Sirius' pharmacogenomic diagnostic intended to assess responsiveness to recombinant human activated Protein C (sold by Eli Lilly and Company under the trademark Xigris (R)) in patients with severe sepsis at high risk of death.
"Access to AP-HP's severe sepsis patients will be critical in the validation of Sirius' sepsis biomarkers and we are delighted to be working with this internationally acclaimed research group," commented Dr. Brad Popovich, President and CEO of Sirius Genomics.
"We are pleased to be a part of this research effort because working with Sirius Genomics will help translate genomic biomarker research in sepsis from the lab bench to the patient bedside," stated Professor Djillali Annane, the Principal Investigator behind two clinical studies that will be utilized in the new collaboration.
Financial terms of the agreement were not disclosed.
About Assistance Publique-Hopitaux de Paris: http://www.aphp.fr/
The Assistance Publique - Hopitaux de Paris is a public health establishment in Paris, France with activities in the field of healthcare, teaching, medical research, prevention, health education, and urgent medical assistance. The AP-HP consists of a 37 hospitals group, and home nursing. It offers patient care based on every diagnostic and therapeutic possibility: all specialists medical areas, structured around 720 medical departments, are represented. It is linked to 7 faculties of medicine, 2 dentistry faculties and 2 pharmacy faculties. The Clinical Research and Development Department (DRCD) of the AP-HP coordinates more than 2000 clinical trials, institutional and industrial sponsorships combined.
About Sirius Genomics: www.siriusgenomics.com
Sirius Genomics is a drug-enabling company that develops pharmacogenomic (PGx) diagnostics that lead to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.
This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.
|SOURCE Sirius Genomics Inc.|
Copyright©2009 PR Newswire.
All rights reserved